• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[抗心律失常药物对窦性心律的药理恢复与维持]

[Pharmacological restoration and maintenance of sinus rhythm by antiarrhythmic agents].

作者信息

Sugi K

机构信息

Third Department of Internal Medicine, Toho University School of Medicine, Ohashi Hospital, Tokyo.

出版信息

J Cardiol. 1999 Mar;33 Suppl 1:59-64.

PMID:10342138
Abstract

Paroxysmal atrial fibrillation is defined as an atrial fibrillation that terminates spontaneously. It is desirable that atrial fibrillation should be terminated immediately after onset, and should be prevented from re-initiation to avoid atrial electrical remodeling or atrial stunning after cardioversion. Antiarrhythmic agents are used for these reasons. The important factors for pharmacological cardioversion of atrial fibrillation are thought to be prolongation of atrial refractory and suppression of conduction time in the atrium. Therefore, class Ia and Ic antiarrhythmic drugs, including bepridil as class IV because of its characteristics of class Ia, are administered to restore sinus rhythm. Verapamil and diltiazem, or beta adrenergic blocker, or digitalis decreases the ventricular response during atrial fibrillation for disturbance of atrioventricular nodal conduction, and then cardioversion of atrial fibrillation may occur. Suppression of supraventricular extrasystoles and atrial conduction time, or prolongation of atrial refractoriness will be needed to maintain sinus rhythm. Class I, III, or bepridil as class IV excepting lidocaine and mexiletine are used to prevent paroxysmal atrial fibrillation. In general, sodium channel blocker is superior for defibrillation and potassium channel blocker is superior for prophylaxis of atrial fibrillation. Considering efficacy, antiarrhythmic agents should be selected depending on the following factors: cardiac function, renal or hepatic function, underlying heart disease, exercise-induced or enhanced mental condition, cholinergic induced, drug-resistant atrial fibrillation or not.

摘要

阵发性心房颤动被定义为自发终止的心房颤动。理想的情况是心房颤动发作后应立即终止,并应防止其再次发作,以避免复律后出现心房电重构或心房顿抑。基于这些原因使用抗心律失常药物。心房颤动药物复律的重要因素被认为是延长心房不应期和抑制心房内的传导时间。因此,Ia类和Ic类抗心律失常药物,包括因其具有Ia类特征而归类为IV类的苄普地尔,被用于恢复窦性心律。维拉帕米、地尔硫䓬,或β肾上腺素能阻滞剂,或洋地黄可因房室结传导紊乱而降低心房颤动时的心室反应,进而可能发生心房颤动的复律。维持窦性心律需要抑制室上性期前收缩和心房传导时间,或延长心房不应期。I类、III类,或除利多卡因和美西律外归类为IV类的苄普地尔被用于预防阵发性心房颤动。一般来说,钠通道阻滞剂在除颤方面更具优势,而钾通道阻滞剂在预防心房颤动方面更具优势。考虑到疗效,应根据以下因素选择抗心律失常药物:心功能、肾或肝功能、基础心脏病、运动诱发或精神状态增强、胆碱能诱发、是否为药物抵抗性心房颤动。

相似文献

1
[Pharmacological restoration and maintenance of sinus rhythm by antiarrhythmic agents].[抗心律失常药物对窦性心律的药理恢复与维持]
J Cardiol. 1999 Mar;33 Suppl 1:59-64.
2
[Problems with anti-arrhythmia therapy in atrial fibrillation].[心房颤动抗心律失常治疗中的问题]
Z Kardiol. 1994;83 Suppl 5:63-9.
3
[Antiarrhythmic drugs in paroxysmal atrial fibrillation. When and how?].[阵发性心房颤动中的抗心律失常药物。何时及如何使用?]
Arch Mal Coeur Vaiss. 1996 Feb;89 Spec No 1:19-24.
4
[Antiarrhythmic treatments of permanent atrial fibrillation].[永久性心房颤动的抗心律失常治疗]
Rev Prat. 1993 Jun 15;43(12):1523-31.
5
Hybrid therapy of atrial fibrillation.心房颤动的混合治疗
Ital Heart J. 2002 Oct;3(10):571-8.
6
[Drug and electrical therapy of supraventricular tachyarrhythmias].[室上性快速心律失常的药物与电疗法]
Z Kardiol. 2000;89 Suppl 3:68-74.
7
Electropharmacological effects of antiarrhythmic drugs on atrial fibrillation termination. Part II: New insights into the electrophysiological mechanisms of atrial fibrillation termination.抗心律失常药物对心房颤动转复的电药理学效应。第二部分:心房颤动转复电生理机制的新见解。
Ital Heart J. 2003 Jul;4(7):442-7.
8
[Drug prevention of recurrence in paroxysmal and chronic atrial fibrillation].[药物预防阵发性和慢性心房颤动复发]
Z Kardiol. 1994;83 Suppl 5:87-96.
9
[Drug therapy of atrial fibrillation].[心房颤动的药物治疗]
Orv Hetil. 2003 Jun 15;144(24):1199-206.
10
[Pharmacologic treatment of atrial fibrillation].[心房颤动的药物治疗]
Pol Merkur Lekarski. 2008 Oct;25(148):303-8.